Adagene Inc
NASDAQ:ADAG
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.44
4.15
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ADAG stock under the Base Case scenario is 0.924 USD. Compared to the current market price of 2.1935 USD, Adagene Inc is Overvalued by 58%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Adagene Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ADAG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Adagene Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Adagene Inc
Balance Sheet Decomposition
Adagene Inc
Current Assets | 98.8m |
Cash & Short-Term Investments | 95.7m |
Receivables | 31.4k |
Other Current Assets | 3.1m |
Non-Current Assets | 2m |
PP&E | 1.7m |
Other Non-Current Assets | 281.9k |
Current Liabilities | 39.5m |
Accounts Payable | 3.4m |
Accrued Liabilities | 2.8m |
Short-Term Debt | 4.2m |
Other Current Liabilities | 29.1m |
Non-Current Liabilities | 4.7m |
Long-Term Debt | 4.6m |
Other Non-Current Liabilities | 114.1k |
Earnings Waterfall
Adagene Inc
Revenue
|
815.8k
USD
|
Operating Expenses
|
-37.8m
USD
|
Operating Income
|
-37m
USD
|
Other Expenses
|
5.1m
USD
|
Net Income
|
-31.8m
USD
|
Free Cash Flow Analysis
Adagene Inc
USD | |
Free Cash Flow | USD |
ADAG Profitability Score
Profitability Due Diligence
Adagene Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Adagene Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
ADAG Solvency Score
Solvency Due Diligence
Adagene Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Adagene Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADAG Price Targets Summary
Adagene Inc
According to Wall Street analysts, the average 1-year price target for ADAG is 9.2174 USD with a low forecast of 3.535 USD and a high forecast of 19.7505 USD.
Dividends
Current shareholder yield for ADAG is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Contact
IPO
Employees
Officers
The intrinsic value of one ADAG stock under the Base Case scenario is 0.924 USD.
Compared to the current market price of 2.1935 USD, Adagene Inc is Overvalued by 58%.